RussianPatents.com

Method for dermal flap survival growth in reduced circulation with sildenafil

IPC classes for russian patent Method for dermal flap survival growth in reduced circulation with sildenafil (RU 2498414):

G09B23/28 - for medicine

A61P43/00 - Drugs for specific purposes, not provided for in groups ; A61P0001000000-A61P0041000000

A61K31/522 -

Another patents in same IPC classes:

Method of diagnosing affection of peripheral nerves in laboratory animals in remote period of exposure to mercuric chloride / 2497448
Invention relates to field of medicine, in particular to experimental medicine. Stimulatory myography is performed to laboratory animals 9 weeks after exposure to toxicant is stopped. Amplitude of M-response (mV) and duration of M-response (ms) on median nerve are registered. Area of involvement of motor units is calculated. Calculation of canonic value is performed. Obtained results are compared with constant and if Cv is higher than 8.9, conclusion about absence of signs of chronic exposure to mercuric chloride is made, if Cv is lower or equals 8.9, affection of peripheral nerves in remote period of exposure to mercuric chloride is diagnosed.

Method of pharmacological correction of sceletal muscle ischemia with silnedafil including in l-name induced nitrogen oxide deficiency / 2497203
Calf muscle ischemia is simulated, including in a combination with additional simulation of nitrogen oxide deficiency by intraperitoneal introduction of the nitrogen oxide synthesis blocker N-nitro-L-arginine of methyl ester (L-NAME) 25 mg/kg daily for 7 days. In both cases, the ischemia is corrected by intragastric introduction of sildenafil 2.2 mg/kg on the first, third and fifth days of experiment.

Method for simulating prenatal hypoxic encephalopathy in small laboratory animals / 2497202
Sodium nitrite 50 mg/kg is introduced subcutaneously into small laboratory female animals daily from 10^th to 19^th day of pregnancy.

Method for dermal flap survival growth in reduced circulation with minoxidil / 2497201
Dermal flap is simulated in laboratory animals on the second day of the experiment. On the first and fourth day of the experiment, minoxidil is introduced intraperitoneally in a daily dose of 1.0 mg/kg in two stages.

Method for pharmacological correction of sceletal muscle ischemia with minoxidil / 2497200
Calf muscle ischemia is simulated in rats on the second day following the experiment. On the first, fourth and seventh day of the experiment, minoxidil is introduced intragastrically in a daily dose of 1.0 mg/kg in two stages.

Method for simulating bone crystallisation in coxarthrosis in vitro / 2496150
Method involves preparing mineral phases forming the basis of an inorganic matrix of human bone tissue in an artificial medium close to such in the individuals suffering coxarthrosis. That involves preparing the above simulative medium at pH 7.80+0.05. The medium has thee following composition: CaCl₂ - 1.1766 g/l, Na₂HPO₄12H₂O - 6.5514 g/l, NaCl - 3.1892 g/l, MgCl₂-6H₂O - 0.4764 g/l, NaHCO₃ - 2.2680 g/l, Na₂SO₄ - 1.6188 g/l, KCl - 0.3427 g/l. After 30 minutes, the medium is examined for hydroxylapatite compositionally similar to apatite of the bone intercellular substance in the patients suffering coxarthrosis.

Method for assessing antismallpox activity of therapeutic preparations / 2496149
For the purpose of assessing antismallpox activity of therapeutic preparations, a suspension of the above preparation is introduced into the reference and test groups of 8-15-day scrub heterosexual ICR mice of 9-11 g. That is followed by intranasal infection with the monkey pox virus strain V79-1-005. The strain is deposited in the State Collection of the Agents of Viral Infections and Rickettsial Diseases of the Federal State-Funded Institution of Science State Research Centre for Virology and Biotechnology "Vector", registration No V-309. The animal's lung virus concentration is determined to calculate estimated figures (indices) that are used to assess antiviral activity of the preparation. The assessed preparation is administered into mice one day before the infection, on the day of infection and then daily during a period of virus incubation in the animal's body.

Method for simulating hyperactive bladder / 2496148
Rat's vena cava in the lower one-third is ligated. The vein is occluded by tightening by 2/3 of the diameter. If observing an increase of the number of urinations in the experiment group in relation to that in the reference group on the third postoperative day, hyperactive bladder is stated.

Method of dual energy dividing-subtracting mammography / 2495623
Invention relates to field of medicine. In method realisation mammograms at two different energies of irradiation are obtained. Standard with known distributions of density, thickness and effective atomic number is placed neat mammary gland. Coefficients of connection of atomic number with difference and ratio of logarithms of number of photons, which have passed through mammary gland without interaction at two different energies of irradiation are determined and used to visualise its distribution in mammary gland.

Method of estimating blood supply of left half of large intestine in experiment / 2494681
Invention relates to field of medicine, namely to pathological anatomy. To estimate blood supply of left part of large intestine in experiment on human corpse, alternating introduction of dye solution is performed into superior mesenteric artery, internal iliac arteries and into inferior mesenteric artery with further visual observation over spread and intensity of staining of intestine tissues with dye. Introduced dye solution consists of 500 ml of distilled water, 200 g of lead nitrate and 20 ml of 1% of water solution of methylene blue. In order to estimate blood supply of left half of intestine concentration of lead nitrate in percent is determined in samples of intestine tissues by means of low-vacuum scanning electron microscope with system of energy dispersive microanalysis.

Method for early detection of high risk of developing impaired glucose tolerance with underlying metoprolol administration in patients with stable effort angina / 2498306
Metoprolol therapy is preceded by conducting 2 exercise tests on the same day to achieve a load power according to the same protocol, initially and 2 hours after administration of a single dose of metoprolol 50 mg. If observing an interval gain of 120 second and more at the 2nd load as compared to the 1st load from the beginning of the load before an angina attack and/or reduction of an ischemic ST segment on the electrocardiogram at a depth not less than 1 mm, a risk of impaired glucose tolerance is considered to be high. In this case, 4-5 weeks after the routine administration of metoprolol, glucose tolerance is tested. If glucose tolerance is diagnosed, the metoprolol therapy is discontinued. If the 2nd load as compared to the 1st load shows an interval to the angina attack and/or reduction of the ischemic ST segment on the electrocardiogram at a depth less than 1 mm increasing less than by 120 seconds, a risk of developing impaired glucose tolerance is considered to be negligible. In this case, the metoprolol therapy is continued with no additional glucose tolerance test.

Phenylimidazole compounds / 2497811
Present invention refers to organic chemistry, namely to new phenylimidazole derivatives of general formula , wherein R¹ represents a hydrogen atom, a phenyl lower-alkyl group or a pyridyl lower-alkyl group with a benzene ring and a pyridine ring are optionally substituted by 1 or 2 substitutes specified in a group consisting of halogen atoms, cyano group and halogen-substituted lower-alkyl groups; one or R² and R³ represents a hydrogen atom, and another one represents a lower alkoxy group; R⁴ represents a lower-alkyl group, a difurylglyoxal group, a thienyl group or a phenyl group optionally substituted by 1 or 2 substitutes specified in a group consisting of lower-alkyl groups, lower-alkoxy groups, halogen atoms, a carboxyl group, lower alkoxycarbonyl groups, and halogen-substituted lower-alkyl groups; R⁵ and R⁶ are identical or different, and represent a hydrogen atom or a lower alkyl group; R⁷ and R⁸ are identical or different, and represent a hydrogen atom or a lower alkoxy group; provided R¹ represents an unsubstituted phenyl lower-alkyl group, R² represents a lower alkoxy group, R³ represents a hydrogen atom, R⁴ represents an unsubstituted phenyl group or a phenyl group containing 1 or 2 halogen-substituted lower-alkyl groups, and R⁵ represents a hydrogen atom, then R⁶ is other than a hydrogen atom. Also, the invention refers to an LPL activator, an agent for preventing or treating hyperlipidaemia, an agent for treating arteriosclerosis, and an agent for treating obesity on the basis of the compound of formula (1).

Intraoperative combined spectroscopic diagnostic technique for cerebral and spinal tumours / 2497558
Invention refers to medicine, namely to neurooncology, and may be used for the intraoperative diagnosis of cerebral and spinal tumour borders and determination of the tumour resection quality. What is presented is an intraoperative combined spectroscopic diagnostic technique for cerebral and spinal tumours which involve the preoperative preparation including the oral administration of hydrochloride-5-aminolevulinic acid (several hours before the tumour resection). Actually the intraoperative spectroscopic analysis of the tumour marker content in the analysed tissues (5-aminolevelinic acid-induced protoporphyrin IX), as well as its desintegration products, oxygenated and reduced hemoglobin; the tissue scattering properties are varied using broadband and laser geode light source and a fibre-optic probe. The broadband light source is used within the range of 500÷600 nm, while the exiting fluorescent laser/diode light source - at wave length 620÷640 nm. The diffuse-reflectance spectra of the broadband and laser/diode light, as well as fluorescence are recorded at the same time. After the spectroscopic characteristics have been automatically classified, the operative radicality is assessed.

Fibrosis inhibitor / 2497525
Invention refers to pharmaceutics and medicine and concerns a fibrosis inhibitor containing 2-{4-N-(5,6-diphenyl-pyrazin-2-yl)-N-isopropylamino]butyloxy}acetic aci or a pharmaceutically acceptable salt thereof or 2-{4-[N-(5,6-diphenyl-pyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulphonyl)acetamide or a pharmaceutically acceptable salt thereof as an active ingredient for treating interstitial pneumonia, pulmonary fibrosis, scleroderma or hepatic cirrhosis.

Method for maintaining physiological status in newborn calves / 2497519
Method refers to veterinary science and aims at maintaining the physiological status in newborn calves. The method involves using the biologically active substance coredon. Coredon is pre-mixed with ascorbic acid. This mixture is dissolved in water, fed to calves in the amount of 2 g, once a day, from the second after-birth day for 5 days.

Agent for extreme performance stimulation, method for preparing and using it / 2496504
Group of inventions refers to medicine. The agent represents a mixture of peptides of molecular weight 500-900 Da prepared of the brain of cattle and/or pigs of one year old or younger, particularly the midbrain (mesencephalon), namely the central grey substance surrounding the Sylvian aqueduct (aquaeductus cerebri Sylvii) with the peptide mixture concentration in the agent of 5.0-10.0 mg/ml of the aqueous solution or the content of 5.0-10.0 mg/g in a witepsol suppository. The method involves grinding the cattle and/or porcine frozen midbrain, hydrolysis at +20°C in the presence of pepsin, extraction, separation of the extract from ballast substances by separation through materials with retention potential more than 2000 Da, separation of the purified extract by fluid extraction at critical temperature CO₂ 31.1°C and critical pressure 7.3±0.1 atm, separation of the fraction of 500-900 Da, dissolution in water and freeze drying. The agent is applied in the form of the solution in water in the active substance concentration of 5.0-10.0 mg/ml for single parenteral administration in a dose of 10-30 mg, or in the form of a witepsol suppository with the active substance concentration of 5.0-10.0 mg/ml for single rectal administration in a dose of 10-30 mg.

Methods and compositions for treating phenylketonuria / 2496489
Declared invention refers to medicine and aims at treating phenylketonuria. What is declared is a dosage form containing a) phenylalanine-4-hydroxylase and/or phenylalanine ammonia-lyase and b) at least one peptidase, wherein a), b) or both a) and b) have an enteric coating.

Method for increasing radioactive irradiation sensitivity in animals / 2495665
Invention relates to veterinary science and may be used to increase the radioactive irradiation sensitivity in animal tissues. That is ensured by the pre-radiation parenteral administration of gamma-aminobutyric acid lithium salt in a dose of 40 to 120 mg per 1 kg of body weight.

Sip receptor modulators for treating multiple sclerosis / 2495664
Present group of inventions refers to medicine, namely neurology, and concerns treating multiple sclerosis. That is ensured by the oral introduction of the S1P receptor modulator representing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof in a daily dose of 0.5 mg.

FIELD: medicine.

SUBSTANCE: dermal flap is simulated in laboratory animals on the second day of experiment. Sildenafil 2.2 mg/kg is introduced intraperitoneally on the first, third and fifth day of the experiment.

EFFECT: dermal flap survival rate in reduced circulation with no side effects.

1 tbl, 1 ex

The invention relates to medicine, in particular to experimental pharmacology, and can be used for the correction of ischemia.

Closest to the claimed solution is the method of increasing the survival of the flap of skin on the leg of remote ischemic preconditioning described Pokrovsky M.V. et al. the patent RU 2429547 C1.

However, this solution does not assess the impact of sildenafil on vyzyvaet skin flap in conditions of reduced blood circulation.

The advantage of this method is that the activation of mediators of preconditioning - nitric oxide and protein kinases, and the main effector of the link : ATP-dependent potassium channels is pharmacological drug. In addition, it is proved that the applied dose of sildenafil is devoid of unwanted side effects.

The technical result of the invention is to develop a method of increasing survival of skin flaps in conditions of reduced blood circulation involving the use of sildenafil.

The technical result is achieved by the fact that the modeling of the skin flap in conditions of reduced blood circulation on the second day of the experiment, laboratory animal intraperitoneally injected sildenafil at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment.

JV the PROPERTY IS AS follows

Experiments are conducted on white Wistar rats weighing 220-250 g Modeling the skin flap is performed under General anesthesia (chloral hydrate 300 mg/kg intraperitoneally) on the second day of the experiment. Departing 1 cm from the xiphoid process on the white line of the abdomen, pre-planned stencil size, cut out flap: 1 cm - base, 4 cm long, (keeping the supply vessel) is isolated in a plastic bag, the edges of the skin sutured with a continuous suture. Evaluation of the survival of the skin flap is held on the sixth day of the experiment, by measuring the square of the surviving fabric of the flap in the group of animals with the modeling of the skin flap and in the group with the modeling of the skin flap and the introduction of nicorandil.

Sildenafil ("VIAGRA, Pfizer) is introduced intragastrically at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment.

When aggregated data is calculated the average value, standard deviation value. Differences are considered significant at p<0,05.

AN EXAMPLE OF A SPECIFIC IMPLEMENTATION.

The experiments were carried out on white rats male Wistar weighing 220-250 g Experimental animals were divided into following groups:

1. control(n=10);

2. with the use of sildenafil (n=10).

Animals of both groups were simulated skin flap on the second day of the experiment. Under General anesthesia (chloralhydrate mg/kg intraperitoneally), departing 1 cm from the xiphoid process on the white line of the abdomen, pre-planned stencil size, were cut out of the skin flap: 1 cm - base, 4 cm long, (keeping the supply vessel) insulated in a plastic bag, the edges of the skin sutured with a continuous suture. Animals of the second group were injected intraperitoneally sildenafil at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment;

Estimates of survival of skin graft was performed on the sixth day of the experiment, measuring the area of healthy tissue.

The results of the assessment of skin flap survival are presented in table 1.

Table 1
Survival rates of the skin flap in conditions of reduced blood circulation on the 5th day after the simulation (6th day of the experiment) (M±m).
Group (n=10)	The area of healthy tissue flap
cm	%
Modeling of the skin flap (control)	1,6±0,02	40
Modeling of the skin flap + sildenafil	3,0±0,04*	75
Note. * - p≤0,05 when compared with the control group; sildenafil intragastrically at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment;

Introduction experimental animals sildenafil contributed significant (p<0,05) increase the area of the surviving fabric of the flap.

Thus, the results obtained lead to the conclusion that the increase in skin flap survival in conditions of reduced blood circulation, modeled on the second day of the experiment, intraperitoneal injection of the experimental animal of sildenafil at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment.

A way to increase the skin flap survival in conditions of reduced blood circulation, characterized in that the modeling of the skin flap in conditions of reduced blood circulation on the second day of the experiment laboratory animal intraperitoneally injected sildenafil at a dose of 2.2 mg/kg on the first, third and fifth day of the experiment.